BR112012022676A2 - composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit - Google Patents
composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kitInfo
- Publication number
- BR112012022676A2 BR112012022676A2 BR112012022676A BR112012022676A BR112012022676A2 BR 112012022676 A2 BR112012022676 A2 BR 112012022676A2 BR 112012022676 A BR112012022676 A BR 112012022676A BR 112012022676 A BR112012022676 A BR 112012022676A BR 112012022676 A2 BR112012022676 A2 BR 112012022676A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunogenic composition
- vaccine
- disease
- strains
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit. a presente invenção se refere ao campo e composições imunogênicas e vacinas de neisserial, sua fabricação e o uso de tais composições na medicina. em particular a presente invenção se refere a composições e métodos que envolve o antígeno de proteína de ligação dp fator h (fhbp). foi reconhecido que fhbp é deficientemente expressado em cepas de neisserial de complexo clonal st269 (um subconjunto de cepas que parece estar crescendo em termos de números de casos relatados de doença atribuída a elas) e vacinas que compreendem fhbp podem ser tornados mais eficazes contra as ditas cepas pela formulação da vacina com um antígeno adicional que pode eliciar proteção contra estas cepas.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31257410P | 2010-03-10 | 2010-03-10 | |
US31258210P | 2010-03-10 | 2010-03-10 | |
US31255010P | 2010-03-10 | 2010-03-10 | |
US31279210P | 2010-03-11 | 2010-03-11 | |
US31280410P | 2010-03-11 | 2010-03-11 | |
US31279910P | 2010-03-11 | 2010-03-11 | |
PCT/EP2011/053632 WO2011110636A1 (en) | 2010-03-10 | 2011-03-10 | Immunogenic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012022676A2 true BR112012022676A2 (pt) | 2019-09-24 |
Family
ID=43983531
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012022669A BR112012022669A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. |
BR112012022688A BR112012022688A2 (pt) | 2010-03-10 | 2011-03-10 | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão |
BR112012022676A BR112012022676A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012022669A BR112012022669A2 (pt) | 2010-03-10 | 2011-03-10 | composição imunogênica, método de tratamento ou prevenção de infecção ou doença, uso de um antígeno, kit, métodos para a fabricação de uma composição imunogênica e para melhorar uma vacina. |
BR112012022688A BR112012022688A2 (pt) | 2010-03-10 | 2011-03-10 | proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão |
Country Status (7)
Country | Link |
---|---|
US (4) | US20130011429A1 (pt) |
EP (3) | EP2544712A1 (pt) |
JP (4) | JP2013521770A (pt) |
CN (3) | CN102869378A (pt) |
BR (3) | BR112012022669A2 (pt) |
CA (3) | CA2792689A1 (pt) |
WO (3) | WO2011110634A1 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2270172T3 (en) | 1999-05-19 | 2016-02-29 | Glaxosmithkline Biolog Sa | Combination Compositions of Neisseria. |
MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
ES2532946T3 (es) | 2008-02-21 | 2015-04-06 | Novartis Ag | Polipéptidos PUfH meningocócicos |
NZ595234A (en) | 2009-03-24 | 2013-12-20 | Novartis Ag | Adjuvanting meningococcal factor h binding protein |
JP2013521770A (ja) * | 2010-03-10 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
WO2012025873A2 (en) | 2010-08-23 | 2012-03-01 | Wyeth Llc | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS |
JP5976652B2 (ja) | 2010-09-10 | 2016-08-24 | ワイス・エルエルシー | 髄膜炎菌orf2086抗原の非脂質化変異体 |
EP2823312B1 (en) | 2012-03-08 | 2019-08-07 | GlaxoSmithKline Biologicals SA | In vitro potency assay for protein-based meningococcal vaccines |
EP3485906A1 (en) | 2012-03-09 | 2019-05-22 | Pfizer Inc | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
US9427476B2 (en) | 2012-05-24 | 2016-08-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent meningococcal conjugates and methods for preparing conjugates |
WO2013186753A1 (en) * | 2012-06-14 | 2013-12-19 | Novartis Ag | Vaccines for serogroup x meningococcus |
CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
KR20180099912A (ko) | 2013-09-08 | 2018-09-05 | 화이자 인코포레이티드 | 나이세리아 메닌지티디스 조성물 및 그의 방법 |
CN104248755A (zh) * | 2013-10-30 | 2014-12-31 | 普莱柯生物工程股份有限公司 | 一种副猪嗜血杆菌病疫苗组合物及其制备方法和应用 |
WO2015128480A1 (en) | 2014-02-28 | 2015-09-03 | Novartis Ag | Modified meningococcal fhbp polypeptides |
CN106795208A (zh) | 2014-07-17 | 2017-05-31 | 葛兰素史密丝克莱恩生物有限公司 | 修饰的脑膜炎球菌fHbp多肽 |
CN106659776A (zh) * | 2014-07-17 | 2017-05-10 | 葛兰素史密丝克莱恩生物有限公司 | 脑膜炎球菌疫苗 |
US10888611B2 (en) | 2015-02-19 | 2021-01-12 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
US11066453B2 (en) * | 2015-05-18 | 2021-07-20 | Biomvis Srl | Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof |
US20180064801A1 (en) * | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
SG10202111092UA (en) | 2017-01-31 | 2021-11-29 | Pfizer | Neisseria meningitidis compositions and methods thereof |
BR102020013216A2 (pt) * | 2020-06-26 | 2022-03-08 | Instituto Butantan | Processo de obtenção de vesículas apresentadoras de antígenos (vaa) que possibilita o acoplamento de um ou mais antígenos |
US20220265805A1 (en) * | 2021-02-19 | 2022-08-25 | Sanofi Pasteur Inc. | Meningococcal b recombinant vaccine |
CN113896799B (zh) * | 2021-09-10 | 2023-07-21 | 江苏南农高科技股份有限公司 | 一种融合蛋白、融合蛋白疫苗及其制备方法、应用 |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2848965A1 (de) | 1978-11-11 | 1980-05-22 | Behringwerke Ag | Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine |
EP0027888B1 (en) | 1979-09-21 | 1986-04-16 | Hitachi, Ltd. | Semiconductor switch |
US4271147A (en) | 1980-01-10 | 1981-06-02 | Behringwerke Aktiengesellschaft | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
RU2023448C1 (ru) | 1987-07-30 | 1994-11-30 | Сентро Насьональ Де Биопрепарадос | Способ получения вакцины против различных патогенных серотипов менингита нейссера группы в |
CA2005704C (en) | 1988-12-16 | 2003-02-11 | James C. Paton | Pneumolysin mutants and pneumococcal vaccines made therefrom |
ES2202297T3 (es) | 1990-07-16 | 2004-04-01 | University Of North Carolina At Chapel Hill | Proteinas antigenicas de n. meningitidis reprimibles con hierro relacionadas con la familia de toxinas hemolisina. |
US5912336A (en) | 1990-08-23 | 1999-06-15 | University Of North Carolina At Chapel Hill | Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis |
DK0546118T3 (da) | 1990-08-23 | 2004-02-16 | Univ North Carolina | Transferrinbindende proteiner fra Neisseria gonorrhoeae og Neisseria meningtidis |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5652211A (en) | 1991-02-11 | 1997-07-29 | Biosynth S.R.L. | Peptides for neutralizing the toxicity of Lipid A |
US5371186A (en) | 1991-02-11 | 1994-12-06 | Biosynth S.R.L. | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |
US6592876B1 (en) | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
FR2682041B1 (fr) | 1991-10-03 | 1994-01-14 | Pasteur Merieux Serums Vaccins | Vaccin contre les infections a neisseria meningitidis. |
CA2127871A1 (en) | 1992-01-13 | 1993-07-22 | Andreas Herman Hogt | Crosslinking of rubbers with engineering plastics |
DE69333107T2 (de) | 1992-02-11 | 2004-01-29 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
FR2692592B1 (fr) | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
UA40597C2 (uk) | 1992-06-25 | 2001-08-15 | Смітклайн Бічем Байолоджікалс С.А. | Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів |
GB9224584D0 (en) | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
DE69431624T2 (de) | 1993-05-18 | 2003-07-10 | Univ Ohio State Res Found | Impfstoff gegen mittelohrentzündung |
CA2175332C (en) | 1993-11-08 | 2009-04-07 | Sheena M. Loosmore | Haemophilus transferrin receptor genes |
US6361779B1 (en) | 1993-11-08 | 2002-03-26 | Aventis Pasteur Limited | Transferrin receptor genes |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
CA2560114A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US5565204A (en) | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
EA199800046A1 (ru) | 1995-06-07 | 1998-06-25 | Байокем Вэксинс Инк. | Полипептид, последовательность днк, вакцинная композиция (варианты), антитело или его фрагмент, вакцина, применения указанных полипептида, последовательности днк и антитела или его фрагмента |
GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
US6440701B1 (en) | 1996-03-08 | 2002-08-27 | Aventis Pasteur Limited | Transferrin receptor genes of Moraxella |
US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
EP0912608B1 (en) | 1996-05-01 | 2006-04-19 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
FR2751000B1 (fr) | 1996-07-12 | 1998-10-30 | Inst Nat Sante Rech Med | Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques |
US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
US5882871A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | Saliva binding protein |
AU6909098A (en) | 1996-10-31 | 1998-05-22 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
CA2292838A1 (en) | 1997-06-03 | 1998-12-10 | Connaught Laboratories Limited | Lactoferrin receptor genes of moraxella |
US6764686B2 (en) | 1997-07-21 | 2004-07-20 | Baxter International Inc. | Modified immunogenic pneumolysin compositions as vaccines |
CN1204253C (zh) | 1997-08-15 | 2005-06-01 | 乌得勒支大学 | 奈瑟氏球菌乳铁蛋白结合蛋白 |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
CA2264970A1 (en) | 1998-03-10 | 1999-09-10 | American Cyanamid Company | Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria |
CA2325340A1 (en) | 1998-04-07 | 1999-10-14 | Medimmune, Inc. | Derivatives of pneumococcal choline binding proteins for vaccines |
GB9808734D0 (en) | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
GB9808866D0 (en) | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
GB9811260D0 (en) | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel compounds |
GB9814902D0 (en) | 1998-07-10 | 1998-09-09 | Univ Nottingham | Screening of neisserial vaccine candidates against pathogenic neisseria |
US6951652B2 (en) | 1998-07-29 | 2005-10-04 | Biosynth S.R.L. | Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases |
GB9820003D0 (en) | 1998-09-14 | 1998-11-04 | Smithkline Beecham Biolog | Novel compounds |
DE69926647T2 (de) | 1998-10-16 | 2006-11-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Durch molekulares pathogenicid vermittelte krankheitsresistenz in pflanzen |
GB9823978D0 (en) | 1998-11-02 | 1998-12-30 | Microbiological Res Authority | Multicomponent meningococcal vaccine |
ES2294821T5 (es) | 1998-11-03 | 2014-03-05 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | LPS con toxicidad reducida a partir de bacterias gram negativas modificadas genéticamente |
ATE451461T1 (de) | 1999-03-12 | 2009-12-15 | Glaxosmithkline Biolog Sa | Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
DK2270172T3 (en) | 1999-05-19 | 2016-02-29 | Glaxosmithkline Biolog Sa | Combination Compositions of Neisseria. |
CA2378687A1 (en) | 1999-06-18 | 2000-12-28 | Elitra Pharmaceuticals, Inc. | Nucleotide sequences of moraxella catarrhalis genome |
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
WO2001055182A1 (en) | 2000-01-25 | 2001-08-02 | The University Of Queensland | PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA |
GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
US20060034854A1 (en) * | 2002-08-02 | 2006-02-16 | Berthet Francois-Xavier J | Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria |
GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
MXPA05011110A (es) * | 2003-04-16 | 2006-01-24 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. |
CA2550927A1 (en) * | 2003-12-23 | 2005-07-14 | Glaxosmithkline Biologicals S.A. | A gram negative bacterium with reduced lps level in the outer membrane and use thereof for treating gram negative bacterial infection |
CA2590974C (en) * | 2005-01-27 | 2017-10-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
CA2654709A1 (en) * | 2006-06-12 | 2007-12-21 | Nathalie Devos | Neisseria meningitidis lipooligosaccharide vaccine |
GB0700562D0 (en) * | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
BRPI0814793A2 (pt) * | 2007-08-02 | 2015-02-03 | Glaxosmithkline Biolog Sa | Método de tipagem molecular los de uma cepa neisseria, kit, e, método de diagnóstico e classificação de uma colonização de neisseria e/ou infecção em um hospedeiro susceptível à colonização de neisseria. |
AU2009223613B2 (en) | 2008-03-10 | 2014-09-25 | Children's Hospital & Research Center At Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
MX2010012999A (es) * | 2008-05-30 | 2012-03-07 | U S A As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army | Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso. |
GB0816447D0 (en) * | 2008-09-08 | 2008-10-15 | Glaxosmithkline Biolog Sa | Vaccine |
GB0819633D0 (en) * | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
NZ595234A (en) * | 2009-03-24 | 2013-12-20 | Novartis Ag | Adjuvanting meningococcal factor h binding protein |
US20130022633A1 (en) * | 2009-10-27 | 2013-01-24 | University Of Florence | MENINGOCOCCAL fHBP POLYPEPTIDES |
JP2013521770A (ja) * | 2010-03-10 | 2013-06-13 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン組成物 |
US9473463B2 (en) | 2014-07-29 | 2016-10-18 | Combined Conditional Access Development & Support, LLC | Control word and associated entitlement control message caching and reuse |
-
2011
- 2011-03-10 JP JP2012556521A patent/JP2013521770A/ja active Pending
- 2011-03-10 JP JP2012556523A patent/JP2013521327A/ja active Pending
- 2011-03-10 BR BR112012022669A patent/BR112012022669A2/pt not_active IP Right Cessation
- 2011-03-10 EP EP11707192A patent/EP2544712A1/en not_active Withdrawn
- 2011-03-10 US US13/583,163 patent/US20130011429A1/en not_active Abandoned
- 2011-03-10 US US13/583,314 patent/US9567377B2/en active Active
- 2011-03-10 WO PCT/EP2011/053630 patent/WO2011110634A1/en active Application Filing
- 2011-03-10 WO PCT/EP2011/053631 patent/WO2011110635A1/en active Application Filing
- 2011-03-10 WO PCT/EP2011/053632 patent/WO2011110636A1/en active Application Filing
- 2011-03-10 CN CN2011800231104A patent/CN102869378A/zh active Pending
- 2011-03-10 JP JP2012556522A patent/JP2013521326A/ja active Pending
- 2011-03-10 CN CN2011800231068A patent/CN102869377A/zh active Pending
- 2011-03-10 CA CA2792689A patent/CA2792689A1/en not_active Abandoned
- 2011-03-10 EP EP11708449A patent/EP2544714A1/en not_active Withdrawn
- 2011-03-10 CA CA2792683A patent/CA2792683A1/en not_active Abandoned
- 2011-03-10 CN CN2011800220453A patent/CN103002910A/zh active Pending
- 2011-03-10 CA CA2792687A patent/CA2792687A1/en not_active Abandoned
- 2011-03-10 BR BR112012022688A patent/BR112012022688A2/pt not_active IP Right Cessation
- 2011-03-10 US US13/583,064 patent/US20130004530A1/en not_active Abandoned
- 2011-03-10 EP EP11707193A patent/EP2544713A1/en not_active Withdrawn
- 2011-03-10 BR BR112012022676A patent/BR112012022676A2/pt not_active IP Right Cessation
-
2016
- 2016-12-06 US US15/370,450 patent/US20170209562A1/en not_active Abandoned
-
2017
- 2017-02-02 JP JP2017017175A patent/JP2017114874A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2011110636A1 (en) | 2011-09-15 |
US20130004530A1 (en) | 2013-01-03 |
JP2013521770A (ja) | 2013-06-13 |
WO2011110634A1 (en) | 2011-09-15 |
US20130045231A1 (en) | 2013-02-21 |
EP2544713A1 (en) | 2013-01-16 |
CA2792687A1 (en) | 2011-09-15 |
US20130011429A1 (en) | 2013-01-10 |
US9567377B2 (en) | 2017-02-14 |
EP2544712A1 (en) | 2013-01-16 |
BR112012022669A2 (pt) | 2017-02-14 |
CN103002910A (zh) | 2013-03-27 |
CA2792683A1 (en) | 2011-09-15 |
EP2544714A1 (en) | 2013-01-16 |
CA2792689A1 (en) | 2011-09-15 |
US20170209562A1 (en) | 2017-07-27 |
CN102869378A (zh) | 2013-01-09 |
WO2011110635A1 (en) | 2011-09-15 |
BR112012022688A2 (pt) | 2018-05-22 |
JP2017114874A (ja) | 2017-06-29 |
JP2013521327A (ja) | 2013-06-10 |
JP2013521326A (ja) | 2013-06-10 |
CN102869377A (zh) | 2013-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012022676A2 (pt) | composição imunogênica, métodos para tratamento ou prevenção de infecção ou doença, para fabricar uma composição imunogênica e para melhorar uma vacina, e, kit | |
BR112012022800A2 (pt) | composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica | |
CL2017000830A1 (es) | Formulación estable que comprende un azúcar no reductora, un anticuerpo anti-s4b7 y al menos un aminoácido libre; un método para preparar dicha formulación; uso de dicha formulación para tratar una enfermedad inflamatoria del intestino. | |
NZ628449A (en) | Neisseria meningitidis compositions and methods thereof | |
EP3916091A3 (en) | Dry powder composition comprising long-chain rna | |
BRPI1013780B8 (pt) | Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica | |
UY31942A (es) | Formulaciones de adyuvante comprendiendo combinaciones de triterpenoides, esteroles, inmunomoduladores, polímeros y estimuladores de th2, procedimientos de preparación, composiciones y aplicaciones. | |
BR112013005427A2 (pt) | composição imunogênica, vacina, método para tratamento ou prevenção de doença, e para preparar a composição imunogênica ou vacina, uso da vacina,e, composição farmacêutica. | |
BR112013006396A2 (pt) | composições imunogênicas | |
SG158870A1 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
WO2012025873A3 (en) | STABLE FORMULATIONS OF NEISSERIA MENINGITIDIS rLP2086 ANTIGENS | |
MX2009006178A (es) | Vacuna contra salmonela. | |
BR112015005056A2 (pt) | vacinas de combinação com sorogrupo b meningococcus e d/t/p | |
WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
BRPI0918806A2 (pt) | composição compreendendo quitosana para administração ocular de vaninas em aves | |
BR112014000843A8 (pt) | Uso de picosulfato para preparação de composição intestinal para o cálculo da duração de colonoscopia, composição intestinal e kit | |
BR112013018642A2 (pt) | vacinas e composições contra streptococcus pneumoniae | |
MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
BR112012025678A2 (pt) | composição para inibição da transmissão do hiv, uso da mesma, métood para preparação da mesma e método para inibição de transmissão do hiv. | |
BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
BR112016030294A2 (pt) | Cepa de bactérias probióticas de lactobacillus e uma vacina de aves domésticas, composição, ovo de aves domésticas embrionado, kit, e, método de vacinação in ovo de aves domésticas | |
WO2011151723A3 (en) | Concentration of influenza vaccine antigens without lyophilization | |
BR112021020883A2 (pt) | Formas sólidas de um inibidor de glyt1 | |
BR112012013199A8 (pt) | Composto, composição farmacêutica, e , uso de um composto | |
WO2021259743A3 (en) | Klebsiella pneumoniae o-antigen vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law | ||
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |